peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-08-18. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
== History == The pancreas was first identified by Herophilus (335–280 BC), a Greek anatomist and surgeon. A few hundred years later, Rufus of Ephesus, another Greek anatomist, gave the pancreas its name. Etymologically, the term "pancreas", a modern Latin adaptation of Greek πάγκρεας, [πᾶν ("all", "whole"), and κρέας ("flesh")], originally means sweetbread, although literally meaning all-flesh, presumably because of its fleshy consistency. It was only in 1889 when Oskar Minkowski discovered that removing the pancreas from a dog caused it to become diabetic. Insulin was later isolated from pancreatic islets by Frederick Banting and Charles Best in 1921. The way the pancreatic tissue has been viewed has also changed. Previously, it was viewed using simple staining methods such as H&E stains. Now, immunohistochemistry can be used to differentiate cell types more easily. This involves visible antibodies to the products of certain cell types, and helps identify with greater ease cell types such as alpha and beta cells.
==== Motivation ==== Testosterone levels play a major role in risk-taking during financial decisions. Higher testosterone levels in men reduce the risk of becoming or staying unemployed. Research has also found that heightened levels of testosterone and cortisol are associated with an increased risk of impulsive and violent criminal behavior. On the other hand, elevated testosterone in men may increase their generosity, primarily to attract a potential mate.
=== FluidCrystal technology === Camurus' FluidCrystal are available as injectable depots and topical bioadhesive delivery technologies. By encapsulating the drug compound in the nanostructures, injectable depots are able to deliver therapeutic levels of drug substance over extended periods from a single injection. This leads to a decrease in traditional side effects associated with high initial drug release on injection (drug burst), poor drug stability, and complex processing requirements, making the system highly suitable for sustained parental delivery of peptides, proteins, and small molecule drug compounds. The topical delivery system creates a bio-adhesive film that provides local and continual release of drug compounds. The delivery system is suited for delivery of peptide, protein, and small molecule drug compounds and can be applied to dermal, buccal, ophthalmic, nasal, vaginal, and other topical surfaces.
The 2000s and 2010s saw significant development in industrial automation of molecules as well as the emergence of general synthesis systems that could synthesise a wide variety of molecules on-demand, whose operation Melanie Trobe and Martin D. Burke compared to that of a 3D printer.
== Tracing of illicit drugs == Illegal heroin may be produced using poppy straw as a raw material. The alkaloid profiles of poppy straw and opium are similar, but preliminary research suggests they can be distinguished by relative quantities of alkaloids. Based on the presence of the alkaloid oripavine in some opium poppies, it has been suggested that illegal heroin seized in Australia was produced from a legal poppy straw crop stolen in Tasmania a few years earlier.
Sources: en.wikipedia.org
== Veterinary uses == In 2019, GS-441524 was shown to have promise for treating feline infectious peritonitis caused by a coronavirus. It has not been evaluated or approved by the US Food and Drug Administration (FDA) for the treatment of feline coronavirus or feline infectious peritonitis but has been available since 2019, through websites and social media as an unregulated black market substance. Because GS-441524 is the main circulating metabolite of remdesivir and because GS-441524 has similar potency against SARS-CoV-2 in vitro, some researchers have argued for the direct administration of GS-441524 as a COVID‑19 treatment.
The UK's light-touch regulatory approach has drawn criticism for potentially leaving the public inadequately protected. Organisations like the Ada Lovelace Institute argue for a statutory AI Bill to mandate pre-deployment testing and empower regulators, citing public polling that strongly supports independent regulation. The impact of AI on the labour market is another major concern. Reports suggest that up to three million UK jobs could be displaced by 2035, with lower-skilled and entry-level positions particularly vulnerable. Trade unions, including the Trades Union Congress and Prospect, have raised alarms about the rise of algorithmic management and workplace surveillance, calling for a "pro-worker" AI strategy and the right to disconnect. Furthermore, there are concerns about the UK's dependence on US technology infrastructure, which some argue threatens economic competitiveness and national security, leading to calls for greater "digital sovereignty". The UK faces intense debate over AI developers training models on copyrighted material. Following strong opposition from the creative sector and trade unions, the government abandoned a 2024 proposal that would have allowed broad text and data mining (TDM) with only an "opt-out" for creators. Conversely, academia and libraries argue that narrow TDM exceptions restrict research. They criticise major publishers for charging universities to access research while simultaneously selling that same data to commercial AI developers, often steering authors towards restrictive licences to retain exclusive commercial rights.
Juven is a medical food that is manufactured by Abbott Laboratories and used to provide nutritional support under the care of a physician in individuals with muscle wasting due to AIDS or cancer, to promote wound healing following surgery or injury, or when otherwise recommended by a medical professional. It is a powdered nutritional supplement that contains 3 grams of calcium β-hydroxy β-methylbutyrate, 14 grams of L-arginine, and 14 grams of L-glutamine per two daily servings. Juven has been shown to increase lean body mass during clinical trials in individuals with AIDS and cancer, but not rheumatoid cachexia. Clinical trials with Juven for AIDS have also demonstrated improvements in immune status, as measured by a reduced HIV viral load relative to controls and higher CD3+ and CD8+ cell counts. The efficacy of Juven for the treatment of cancer cachexia was also examined in a phase 3 clinical trial which found a strong trend (i.e., p=.08) for an improvement in lean body mass relative to controls; however, according to the authors of the trial itself and a systematic review that included it, the trial did not adequately test the ability of Juven to prevent or reverse the loss of lean body mass in individuals with cancer cachexia since the majority of participants did not complete the study. Further research involving the treatment of cancer cachexia with Juven over a period of several months is required to adequately determine treatment efficacy.
== Toxicity == The US Food and Nutrition Board has set a daily limit of 35 mg for vitamin B3, unless under medical supervision. At daily doses of nicotinic acid as low as 30 mg, flushing has been reported, always starting in the face and sometimes accompanied by skin dryness, itching, paresthesia, and headache. (These effects do not occur with nicotinamide). Liver toxicity is the most serious toxic reaction and it occurs at doses >2 grams/day, and is possible with either nicotinic acid or nicotinamide. Fulminant hepatic failure has been reported in cases of niacin overdose at several grams per day. Other reactions include glucose intolerance, hyperuricemia, macular edema, and macular cysts.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.